Identify the ingredient before assessing risk
Nicotinic acid, nicotinamide, nicotinamide riboside and nicotinamide mononucleotide are not interchangeable names. ODS describes liver toxicity with high-dose niacin, particularly some formulations. That warning should not be automatically assigned to every precursor, nor ignored because all are linked to NAD metabolism. [1][2]
Short NMN trials are reassuring within limits
A 2026 systematic review found no significant increase in ALT or AST or overall adverse events in the available short-term adult trials. Study durations and sample sizes limit detection of rare or delayed injury, and selected trial participants do not represent every person with established liver disease. [3]
Injection quality is a separate hazard
FDA has reported serious reactions after NAD+ injections and warned about ingredients unsuitable for sterile compounding. Oral supplement tolerability does not establish injectable safety. Product purity, route and additional ingredients must be evaluated separately. [4]
Use the actual exposure in a clinical review
Imagine liver tests change after a new NAD-labelled blend. Bring the bottle, doses, start date and other medicines or supplements to the clinician. Do not assume a biochemical role in metabolism proves either that the product caused the problem or that it protects the liver. [5][3]
| Detail | Why |
|---|---|
| Exact precursor | Risks are not identical |
| Dose and formulation | Affects exposure |
| Trial duration | Limits long-term inference |
| Oral versus injected | Different hazards |

Sources for this article
- Niacin - Health Professional Fact Sheet
Source consulted: 2026-09-21. This is a reference resource, not a claim that we conducted the studies or tested a product. - Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions - PMC
Source consulted: 2026-09-21. This is a reference resource, not a claim that we conducted the studies or tested a product. - Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis - PMC
Source consulted: 2026-09-21. This is a reference resource, not a claim that we conducted the studies or tested a product. - FDA reminds compounders to use ingredients suitable for sterile compounding | FDA
Source consulted: 2026-09-21. This is a reference resource, not a claim that we conducted the studies or tested a product. - Dietary Supplements: What You Need to Know
Source consulted: 2026-09-21. This is a reference resource, not a claim that we conducted the studies or tested a product.